Arcutis Biotherapeutics
ARQT
241 hedge funds and large institutions have $1.97B invested in Arcutis Biotherapeutics in 2025 Q1 according to their latest regulatory filings, with 63 funds opening new positions, 67 increasing their positions, 81 reducing their positions, and 29 closing their positions.
207% more call options, than puts
Call options by funds: $13.1M | Put options by funds: $4.26M
117% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 29
16% more funds holding
Funds holding: 208 → 241 (+33)
10% more capital invested
Capital invested by funds: $1.79B → $1.97B (+$171M)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
4.13% less ownership
Funds ownership: 110.08% → 105.95% (-4.1%)
17% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 81
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$20.6M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
+$6.32M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$5.78M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.32M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$4.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$25.9M |
| 2 |
Jennison Associates
New York
|
-$13.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$13M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$9.45M |
| 5 |
JP Morgan Chase
New York
|
-$8.43M |
ARQT Hedge Fund Activity: Q1 2025 in Review
241 of the 7,473 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q1 2025, worth a combined $1.97B — up 9.5% from $1.79B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new ARQT positions and 29 closed out — a net gain of 34 holders — while 67 added to existing stakes and 81 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $20.6M. The largest seller was Millennium Management, cutting an estimated $25.9M.
- 241 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q1 2025, up from 208 in Q4 2024.
- Funds reported $1.97B of Arcutis Biotherapeutics stock for Q1 2025, up 9.5% quarter-over-quarter.
- 63 funds opened new Arcutis Biotherapeutics positions in Q1 2025 and 29 closed out, a net change of +34 holders.
- The largest Arcutis Biotherapeutics buyer in Q1 2025 was Paradigm Biocapital Advisors, an estimated $20.6M added.
- The largest Arcutis Biotherapeutics seller in Q1 2025 was Millennium Management, an estimated $25.9M sold.
Based on aggregated 13F filings for Q1 2025.